Sequus preclinical data

Two studies presented at the Conference on Human Retroviruses and Opportunistic Infection in Washington demonstrated Doxil's safety and efficacy as a first-line treatment for KS. The trials included 499 patients, of whom 254 were treated with Doxil; 125 received ABV therapy of Adriamycin doxorubicin), bleomycin and vincristine; and 120 received bleomycin and vincristine (BV). Dosing intervals were two weeks in the ABV study and 3 weeks in the BV study. ...